Clinical Trial Update: Bioequivalence Study of Crushed Sofosbuvir/Velpatasvir Compared to the Whole Tablet [Phase 4]

View source ↗

Summary

A Phase 4 bioequivalence study comparing crushed sofosbuvir/velpatasvir to the whole tablet was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Sofosbuvir/Velpatasvir (sofosbuvir/velpatasvir)

Snippet

Sponsor: Radboud University Medical Center | Conditions: HCV | Phase 4 | Status: WITHDRAWN